The majority of endometrial cancer patients are cured by surgical removal of the uterus. Adjuvant treatment is recommended for a subset of patients with tumor characteristics associated with increased risk of recurrence. Historically pathologists have played a central role in defining histopathological factors that together make-up a risk profile which directs the type of adjuvant treatment. This traditional approach suffers from interobserver variability and lacks a biological basis. With the advance of molecular pathology, we have been able to define molecularly distinct endometrial cancer subsets which also carry distinct prognostic information and may form a basis for targeted adjuvant treatment. The RAINBO program exploits this concept by running 4 molecular subclass specific clinical trials. During my talk I will go over the past, the present and the future of adjuvant treatment in endometrial cancer with an emphasis on the role of pathology.

Citation Format: Tjalling Bosse. Personalized adjuvant treatment in endometrial cancer [abstract]. In: Proceedings of the AACR Special Conference on Endometrial Cancer: Transforming Care through Science; 2023 Nov 16-18; Boston, Massachusetts. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(5_Suppl):Abstract nr IA014.